Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.
Zheng YanZhi-Hua YaoShu-Na YaoQing-Xin XiaHai-Ying WangJun-Feng ChuMing SongShuang ZhaoYan-Yan LiuPublished in: Cancer management and research (2020)
Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.
Keyphrases
- stem cell transplantation
- diffuse large b cell lymphoma
- case report
- locally advanced
- early stage
- lymph node
- high dose
- radiation therapy
- radiation induced
- acute myeloid leukemia
- acute lymphoblastic leukemia
- ultrasound guided
- emergency department
- squamous cell carcinoma
- low dose
- rectal cancer
- rheumatoid arthritis
- systemic lupus erythematosus